In addition to combining OMV-based ISV with cancer vaccines, other combinations should be tested, including in situ vaccination and checkpoint inhibitors (anti-CTLA4 and anti-PD1/PDL1 mAbs). The gene discussed is CTLA4; the disease is cancer.